Search - tctmd.com

Displaying 1 - 20 of 133

Sort: Relevancy | Date

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond Townsend

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Presentation TCT 2024

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

What Evaluation is Required for Patient Selection for RDN?

Presenter: Naomi Fisher

October 29, 2024

Presentation TCT 2024

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

Presenter: Michael Bloch

October 29, 2024

Presentation TCT 2024

What’s Next - Going into 2025

Presenter: Vijay Iyer

October 28, 2024

Presentation TCT 2024

Science of Ultrasound RDN

Presenter: Michael Joner

October 28, 2024

Presentation TCT 2024

Getting Started: Establishing a Patient Care Pathway

Presenter: Matheen Khuddus

October 28, 2024

Presentation TCT 2024

Building Real-world Clinical Evidence: Global Paradise System (GPS) Registry

Presenter: Naomi Fisher

October 28, 2024

Presentation TCT 2024

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

Presenter: Roland Schmieder

October 28, 2024

Presentation TCT 2024

TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database

Presenter: Manasa Jasti

October 28, 2024

Presentation TCT 2024

TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose

Presenter: Abraham Tzafriri

October 28, 2024

Presentation TCT 2024

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

Presenter: Daria Feshchenko

October 28, 2024

Presentation TCT 2024

TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation

Presenter: Karl Fengler

October 28, 2024

Presentation TCT 2024

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation Controversies and Advances 2023

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Presenter: Michael J. Bloch

November 30, 2023

Presentation TCT 2023

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

Presenter: Michael Bloch

October 25, 2023

Presentation TCT 2023

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

Presenter: Felix Mahfoud

October 25, 2023

Advertisement

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

What Evaluation is Required for Patient Selection for RDN?

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

What’s Next - Going into 2025

Science of Ultrasound RDN

Getting Started: Establishing a Patient Care Pathway

Building Real-world Clinical Evidence: Global Paradise System (GPS) Registry

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database

TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Renal Denervation Will Be an Option for Most Hypertensive Patients!

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content